Celcuity Inc. (NASDAQ:CELC) Short Interest Up 6.4% in January

Celcuity Inc. (NASDAQ:CELC) was the recipient of a significant growth in short interest in the month of January. As of January 31st, there was short interest totalling 3,330,000 shares, a growth of 6.4% from the January 15th total of 3,130,000 shares. Based on an average trading volume of 283,600 shares, the short-interest ratio is currently 11.7 days.

Celcuity Price Performance

NASDAQ CELC traded down $0.12 during trading hours on Tuesday, reaching $12.76. 230,522 shares of the stock traded hands, compared to its average volume of 229,775. The stock has a 50 day simple moving average of $12.26 and a two-hundred day simple moving average of $14.10. Celcuity has a 1 year low of $10.35 and a 1 year high of $22.19. The company has a debt-to-equity ratio of 0.65, a current ratio of 10.35 and a quick ratio of 10.36. The company has a market cap of $473.78 million, a price-to-earnings ratio of -4.89 and a beta of 0.73.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Summit Investment Advisors Inc. boosted its position in shares of Celcuity by 49.5% in the 4th quarter. Summit Investment Advisors Inc. now owns 3,421 shares of the company’s stock worth $45,000 after purchasing an additional 1,132 shares in the last quarter. Acuta Capital Partners LLC raised its stake in Celcuity by 3.6% during the 3rd quarter. Acuta Capital Partners LLC now owns 46,600 shares of the company’s stock valued at $695,000 after buying an additional 1,600 shares during the last quarter. Corebridge Financial Inc. raised its stake in Celcuity by 12.9% during the 4th quarter. Corebridge Financial Inc. now owns 16,256 shares of the company’s stock valued at $213,000 after buying an additional 1,858 shares during the last quarter. nVerses Capital LLC purchased a new stake in Celcuity during the 3rd quarter valued at $33,000. Finally, Prospera Private Wealth LLC purchased a new stake in shares of Celcuity in the 3rd quarter worth $35,000. Hedge funds and other institutional investors own 63.33% of the company’s stock.

Analysts Set New Price Targets

CELC has been the subject of a number of analyst reports. Needham & Company LLC raised their price target on Celcuity from $23.00 to $29.00 and gave the stock a “buy” rating in a report on Thursday, February 6th. HC Wainwright reaffirmed a “buy” rating and issued a $27.00 price target on shares of Celcuity in a report on Friday, November 15th. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Celcuity presently has an average rating of “Buy” and an average price target of $30.17.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.